Podcasts about pneumococcal

Pneumococcal vaccine recommendations are constantly evolving to respond to shifting patterns of infections, which is a good thing. However, the nuances can be complicated to explain to patients. Listen in to learn how experts Richard Colgan, MD and Brenda L. Tesini, MD, discuss changing pneumococcal vaccine recommendations. Topics covered include:  Epidemiologic changes: S. pneumoniae over time Burden on patients and the health system Adjustments to pneumococcal vaccine recommendations Considerations for vaccine selection Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Richard Colgan, MD Professor Emeritus Department of Family and Community Medicine University of Maryland School of Medicine Medical Alumni Association Carolyn Frenkil Selvin Passen History of Medicine Scholar in Residence Baltimore, Maryland Brenda L. Tesini, MD Associate Professor of Medicine, Pediatrics, and Community Health Division of Infectious Diseases University of Rochester Medical Center Rochester, New York Link to program page: https://bit.ly/3RNHkHr Links mentioned in this episode: PneumoRecs VaxAdvisor App for Vaccine Providers | Pneumococcal | CDC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of exciting advancements and strategic moves that are shaping the future of healthcare. Let's start with Pfizer's efforts in pneumococcal vaccination, a testament to the ongoing battle against Streptococcus pneumoniae. With their sights set on expanding protection and combating emerging health threats, Pfizer's initiatives reflect an industry-wide commitment to adapt to microbial challenges, potentially enhancing global public health outcomes. Their work underscores the crucial role vaccines play in preventing severe infections and maintaining public health. In other news, Parabilis Medicines is making strides by eyeing public markets to bolster its phase 3 tumor drug development. This move highlights the increasing reliance on public funding to advance late-stage clinical trials, which are essential for bringing new therapies to patients. Meanwhile, Lilly's acquisition of Engage for $202 million marks a significant expansion into non-viral DNA delivery systems. These systems could address traditional gene therapy challenges, promising more effective and safer genetic medicine options. Immunovant recently decided to discontinue its first-generation FcRn inhibitor after disappointing phase 3 results. This decision illustrates the unpredictable nature of drug development, where clinical evaluations often lead companies to reassess strategies based on trial outcomes. Such pivots are part and parcel of the rigorous scientific process that drives innovation forward. The integration of artificial intelligence in drug discovery is gaining momentum. Incyte's $80 million investment to expand its AI-driven partnership with Genesis is a clear indication of AI's growing importance in optimizing drug discovery. Similarly, Bristol Myers Squibb's collaboration with Anthropics Claude highlights a broader trend of leveraging AI across R&D processes to enhance efficiency and streamline operations. Additionally, Incyte's partnership with Edison Scientific to integrate Kosmos AI across R&D workflows exemplifies AI and machine learning's growing role in enhancing oncology drug discovery processes. Enter Oorja Bio, a newcomer focusing on idiopathic pulmonary fibrosis with a $30 million launch fund. Their novel approach to tackling this debilitating condition exemplifies the innovative spirit within smaller biotech firms aiming to address unmet medical needs. Oorja Bio's efforts are part of a larger movement in biotech where new entrants are making significant impacts by targeting specific diseases with fresh perspectives. On the regulatory front, Gilead has expanded its partnership with Korean manufacturer Yuhan through a $140 million deal for active pharmaceutical ingredients. This strategic move ensures robust supply chains amid evolving regulatory standards and market demands, underscoring the importance of global partnerships in maintaining drug availability and quality. Turning our attention to oncology, the American Society of Clinical Oncology (ASCO) 2026 conference is poised to be a significant event for industry professionals. The focus this year includes precision oncology and evolving trial designs, particularly for pancreatic cancer. The complexity of oncology studies demands tailored solutions for efficacy and regulatory compliance, pushing toward more adaptive and patient-centric trial designs. City of Hope's participation at ASCO emphasizes collaborative efforts in cancer research, combining cutting-edge science with comprehensive patient care to translate breakthroughs into tangible improvements in outcomes. Labcorp's involvement further underscores precision oncology's role through biomarker-driven trials and companion diagnostic development. The conversation at ASCO 2026 will also explore the future design of pancreatic cancer trials. By incorporating external controls and real-world data, researchers aim to streamline processes and expedite access to new therapies, acknowledging pancreatic cancer's unique challenges. In other significant advancements, UCB's Bimzelx showed superior efficacy over Skyrizi in treating psoriatic arthritis during a Phase 3 trial. As an IL-17A/IL-17F inhibitor, Bimzelx represents a promising biologic therapy option, potentially setting new standards in autoimmune treatment. Roche's voluntary license agreement with Medicines Patent Pool for Xofluza accessibility highlights efforts towards global health equity, ensuring essential medications reach low- and middle-income countries. Finally, financial movements such as Mentari Therapeutics' reverse merger raise substantial capital for neurological therapies, exemplifying ongoing investment confidence within the sector. These stories collectively illustrate an era marked by scientific innovation, strategic partnerships, and technological integration aimed at improving patient care and accelerating drug development pathways. As we continue to explore these advancements on Pharma Daily, stay tuned for more insights into how these developments shape our industry's future. That's all for today's episode of Pharma Daily. Thank you for tuning in as we navigate through these transformative times in pharmaceuticals and biotechnology.Support the show

Moon Nahm, M.D., professor emeritus at UAB Department of Medicine and Director of the World Health Organization's Pneumococcal Serology Reference Laboratory at UAB, discusses his career in pneumococcal immunology. From uncovering the WU2 reference strain and other hidden serotypes to pioneering Multiplexed Opsono-Phagocytosis Assay (MOPA) to measure the functional activity of anti-pneumococcal antibodies, Nahm's contributions have facilitated development of advanced vaccines with broader protection and accessibility. Links for This Episode UAB Spotlight on Moon Nahm. Discovery and Characterization of Pneumococcal Serogroup 36 Capsule Subtypes, Serotypes 36A and 36B. Journal of Clinical Microbiology paper, March 27, 2003. A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cpsFragment from an Oral Streptococcus. mBio, May 19, 2020. 50 years—and change. WashU Magazine. MTM Listener Survey

Experts shed light on the latest updates in pneumococcal disease and vaccinations, including updated guideline recommendations, how to apply them to different patient populations, and innovations to increase pharmacist administration of vaccines and associated patient education. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/JNR865. EBAC/CME credit will be available until 8 December 2026.Shielding Generations With Pneumococcal Vaccination Approaches Across the Lifespan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Megan Smith, PharmD, joined Over the Counter to discuss continuously updated pneumococcal vaccines and the pharmacist's role among the greater health care community in managing pneumococcal diseases.

Dr. Stephen Jumic, hospital medicine at Northwestern Medicine Palos Hospital, joins Wendy Snyder, filling in for John Williams, to talk about flu cases increasing, how dangerous the flu can be, the importance of getting vaccinated, if you should get a vaccine if you already had the flu, and if it’s too late to get a […]

Dr. Stephen Jumic, hospital medicine at Northwestern Medicine Palos Hospital, joins Wendy Snyder, filling in for John Williams, to talk about flu cases increasing, how dangerous the flu can be, the importance of getting vaccinated, if you should get a vaccine if you already had the flu, and if it’s too late to get a […]

Dr. Stephen Jumic, hospital medicine at Northwestern Medicine Palos Hospital, joins Wendy Snyder, filling in for John Williams, to talk about flu cases increasing, how dangerous the flu can be, the importance of getting vaccinated, if you should get a vaccine if you already had the flu, and if it’s too late to get a […]

Vidcast:  https://www.instagram.com/p/DQdjEezCeTe/With all the confusion and lack of credible information coming from the usual public health channels, I want to arm all you parents and grandparents with the latest immunization recommendations from the American Academy of Pediatrics.  These guidelines are all based on the latest scientific information which demonstrates that these vaccines are safe and very, very effective at preventing and/or minimizing the effects of sometimes deadly childhood diseases. Now let's review, by months and years, the AAP immunization blueprint. At Birth: The RSV protective antibody nirsevimab up to 6 mos if mom not vaccinated in pregnancy up to 6 mos; 1st dose of Hepatitis B vax. 1 month: Hep B, 2nd dose, to 2 mo.2 months: Rotavirus- RV1 Vax, 2 doses; RV5 Vax, 3 doses, 1st dose; DTaP (Diphtheria, tetanus, and acellular pertussis); Hib (Haemophilus influenzae type b); Pneumococcal; Inactivated Poliovirus4 months: RV1, RV5, 2nd dose; DTaP, Hib, Pneumococcal, Inact Poliovirus, 2nd doses6 months: Hep B, 3rd dose to 18 mo; RV5, 3rd dose; DTaP, 3rd dose; Hib, 3rd dose to 12 mo; Pneumococcal, 3rd dose; Inact Poliovirus, 3rd dose to 18 mo; CoVid, 1 or more doses to 18 yrs; Influenza, 1-2 doses/yr to 6 yrs12 months: Hib, 3rd or 4th dose to 15 mo; Pneumococcal, 4th dose To 15 mo; MMR; Varicella; Hepatitis A, 3 dose series, to 23 mo15 months: DTaP, 4th dose to 18 mo4-6 yrs: DTaP, 5th dose; Inact Poliovirus, 4th dose; MMR, 2nd dose; Varicella, 2nd dose7-10 yrs: HPV, 2 dose series to 12 yrs11-12 yrs: DTap, 6th dose; Meningococcal, 1st dose of 2, second at l6 yrsThese are the vaccines that every child should receive beginning at birth and extending over the first 18 years of life. Look at this as a scorecard for you to follow along with your pediatric team. These days, so many of our families are so mobile, vaccination records may be scattered and not up to date in any single medical record, electronic or otherwise. Your own checklist, either on paper or digital, should be the most complete.I have posted the American Academy of Pediatrics summary chart of all pediatric immunizations on my website at drhowardsmith.com/pediatric-immunizations-2025-6.Summary chart: https://www.drhowardsmith.com/pediatric-immunizations-2025-6AAP guidelines: https://tinyurl.com/467f5c9b#pediatrics #immunizations #vaccines #aap

Vidcast:  https://www.instagram.com/p/DQdknrnjVnr/For nearly the first time in the history of American public health, there is mass confusion and lack of credible information coming from our usual public health channels about which vaccines adults should receive. I want to arm all of you you with the latest immunization recommendations from the American Academy of Family Physicians and the American College of Obstetricians and Gynecologists.  These guidelines are all based on the latest scientific information which demonstrates that these vaccines are safe and very, very effective at preventing and/or minimizing the effects of sometimes deadly diseases. For Pregnant Women since you are immunizing for yourself and your new baby:TDap, in 3rd trimester; Influenza, anytime during flu season; CoVid, anytime; RSV, late 3rd trimester during RSV season.Adults, 18 through 64 year of age: Td/TDap, every 10 years; MMR, if not immune, 1-2 doses; Varicella, if not immune; HPV, through age 26 or 45 if never immunized; Influenza, annually late October; CoVid, 2-3 times a year with latest vaccines; Hepatitis A/B, as needed for travel or chronic illness; Meningitis, as needed for high risk, travel, outbreak, complement deficiency; Pneumococcal, if never immunized, high risk, immunodeficient; RSV,  if never immunized, high risk, immunodeficient.Seniors, 65 years and older: Influenza, yearly, high dose or adjuvated; CoVid: high potency mNEXSPIKE (Moderna) or equivalent Twice yearly, regular potency 2-3 times a year; RSV, single dose ? Every 2 years; Pneumococcal, PCV20 or PCV15+PCV23; Shingles, RZV or Shingrix, 2 dose series at 50 years or more, 19 years or more if immunocompromised; TDap, every 10 years.These are the vaccines that each of us should have. Look at this as a scorecard for you to follow along with your medical team. These days, so many of us are mobile, vaccination records may be scattered and not up to date in any single medical record, electronic or otherwise. Your own checklist, digital or paper, should be the most complete. When you do get a vaccine, let's say at your local pharmacy, be certain to text or email your medical team so that the information can be added to your electronic medical record.I have posted the American Academy of Family Physicians summary chart of all adult immunizations on my website at drhowardsmith.com/adult-immunizations-2025-6.https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules/adult-immunization-schedule.htmlhttps://www.drhowardsmith.com/adult-immunizations-2025-6#adults #pregnancy #seniors #immunizations #vaccines

Steve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Episode 204: Adult Pneumococcal Vaccines in 2025.  Luz Perez (MSIV) presents all the available pneumococcal vaccines for adults. Dr. Arreaza guides the discussion about what to do with adults who have previously received pneumococcal vaccines. Written by Luz Perez, MSIV, Ross University School of Medicine. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Today we're answering a clinic classic: Which pneumococcal vaccine should my adult patient get—and when? This is an update of episode 90.Why pneumococcal vaccines matter?Pneumococcal vaccines prevent infections caused by the bacteria Streptococcus pneumonia. These bacteria can cause serious infections like pneumonia, meningitis, and bacteremia. In 2017, the CDC reports that there were more than 31,000 cases of pneumococcal infections and 3,500 deaths from invasive pneumococcal disease. Children are vaccinated in early childhood, before age 5, with PCV15 or PCV 20, at the age of 2, 4, 6 months and a last dose around 12-15 months. Why do we vaccinate adults?Adults are vaccinated because they're at higher risk of getting pneumococcal disease or of having worse outcomes if they do. Vaccines are important because they protect these at-risk patients and reduce the spread of infections among communities. What are the available vaccines? PCV vs PPSV.There are two pneumococcal vaccines used in practice: a polysaccharide vaccine (PPSV) and a conjugate vaccine (PCV). Both protect by targeting capsular polysaccharides from pneumococcal serotypes most often responsible for invasive disease. In simple terms, these vaccines target a part of the bacteria “coating” and create antibodies or proteins that protect the body when the strep enters the body. PPSV (polysaccharide): PPSV is made from purified pieces of the pneumococcal capsule or coating. The current vaccine PPSV23 (Pneumovax®) covers 23 serotypes (or strains) that were the leading cause of pneumococcal infections in the 1980s. PCV (conjugate): Pneumococcal conjugate vaccines (PCVs) take capsular polysaccharides from the bacterium and chemically link them to a carrier protein, which changes and strengthens the immune response. Current PCVs come in four versions: PCV13 (Prevnar 13)PCV15 (Vaxneuvance)PCV20 (Prevnar 20)PCV21 (Capvaxive) The number indicates the amount of pneumococcal capsule types covered by each vaccine. PCV21 was designed around adult disease patterns and covers many serotypes currently driving invasive disease in adults. However, it does not include serotype 4, but this serotype is covered by the PCV20 and PCV15.Who should be vaccinated? In 2024, the United States Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) updated their recommendations on Pneumococcal vaccinations for adults. Their recommendations are: Everyone 50 years or olderAdults age 19–49 with risks: chronic lung/liver disease, heart failure, diabetes; CSF leak or cochlear implant; immunocompromised states (e.g., HIV, hematologic malignancy, CKD/nephrotic syndrome); functional/anatomic asplenia.Patients with history of prior invasive pneumococcal disease: still vaccinate. What vaccine should be given for adults that have never received the Pneumococcal vaccine?For eligible adults with no prior pneumococcal vaccines, there are three choices:PCV21 oncePCV20 oncePCV15 now, followed by PPSV23 later, usually 1 year; 8 weeks if immunocompromised, CSF leak, or cochlear implant.PCV 20 or PCV21 seem more convenient. Once and done. If available, PCV21 is a great one-and-done pick for most adults because it's tailored to current adult serotypes.Serotype 4 caveat: If your patient is at higher risk for serotype 4 disease—think Navajo Nation, or folks in the Western US/Canada with substance use disorders or experiencing homelessness—choose PCV20 (or PCV15 followed by PPSV23 if PCV20 isn't available).What if the patient already received a Pneumococcal vaccine in the past?Plan depends on which vaccine they received and when.PPSV23 only: give PCV21 ≥1 year later (or PCV20 if serotype-4 risk or PCV21 unavailable).PCV10 or PCV13 only: give PCV21 (or PCV20 if PCV21 unavailable) ≥1 year later. If a PCV is not available, discuss PPSV23 now vs waiting until PCV is available.If patient receives PPSV23 now will need to return ≥1 year later to receive a PCV vaccine, and no more vaccines are needed after that.Is it safe to administer the Pneumococcal vaccine with other vaccines?Coadministration is fine with other non-pneumococcal vaccines, as long as we use different syringes and sites. Data support same-day administration of PPSV23 + influenza, and PCV20 with influenza or mRNA COVID-19 vaccines.Some patients are hesitant to receive vaccines, Are there side effects and contraindications to the vaccine?Local reactions are most common: pain/tenderness; swelling/induration (~20%); redness (~15%). Some people “baby” the arm for a couple of days. These typically resolve in 3–4 days; NSAIDs and warm compresses help.Systemic symptoms: fatigue, headache, myalgias/arthralgias, chills; fever ≥38°C is uncommon (

There are more than 100 known kinds of pneumococcal bacteria. They can cause serious infections in the lungs and other parts of the body. Each year, the U.S. sees about 30,000 cases of pneumococcal disease, which includes blood infections, brain and spine inflammation, and other problems. About 30 percent of cases are among people aged 50 to 64. 有100种已知类型的肺炎球菌细菌。 它们可能在肺部和身体其他部位引起严重的感染。 每年，美国都会看到大约30,000例肺炎球菌疾病，其中包括血液感染，脑和脊柱炎症以及其他问题。 大约30％的病例是50至64岁的人群。 The first pneumococcal vaccine was licensed in the U.S. in 1977. Since then, drugmakers have been coming up with newer versions that target several bacteria in a single shot. 1977年，第一种肺炎球菌疫苗在美国获得了许可。从那时起，制药商就提出了较新的版本，这些版本针对几种细菌。 There are four vaccines now in use. They include Prevnar 20 from Wyeth-Pfizer, and Vaxneuvance and Pneumovax 23 made by Merck. The U.S. Food and Drug Administration this year also approved Merck's Capvaxive, which can cost around $300 a treatment. The new shot can protect against 21 kinds of bacteria, including eight not included in other pneumococcal vaccines. A Merck spokesperson said it is designed to help protect against the bacteria that cause the majority of severe disease in adults aged 50 and older.现在有四种疫苗正在使用。 它们包括来自Wyeth-Pfizer的Prevnar 20，以及由Merck制造的VaxNeuvance和Pneumovax 23。 今年美国食品药品监督管理局还批准了默克的Capvaxive，该公司的每处理费用约为300美元。 新镜头可以预防21种细菌，其中包括其他肺炎球菌疫苗中未包含的8种。 默克公司发言人说，旨在帮助预防50岁及以上成年人的大多数严重疾病的细菌。In June, the CDC advisors recommended the vaccine as a possible shot for adults at higher risk. At the time, the group also talked about the possibility of lowering the age recommendation for older adults. They noted that infections causing sickness peak at age 55 to 59 among Black Americans — a lower age than found among white Americans. 6月，CDC顾问建议该疫苗可能是面对较高风险的成年人的可能性。 当时，该小组还谈到了降低老年人年龄建议的可能性。 他们指出，在黑人美国人中导致疾病峰值55至59岁的感染峰 - 比美国白人的年龄低。 Some scientists have concerns about the CDC recommendation. They say a second treatment, called a booster, may be necessary in about 15 years. And some new vaccines in development could force another update to the recommendations. 一些科学家对CDC建议感到担忧。 他们说，在大约15年内可能需要第二次称为助推器的治疗方法。 开发中的一些新疫苗可能会迫使建议另一项更新。 Dr. Jamie Loehr is the chair of the committee's pneumococcal working group. He was the only person to vote against the proposal. 杰米·洛尔（Jamie Loehr）博士是委员会肺炎球员工作组的主席。 他是唯一反对该提案的人。 He said, “Pneumococcal has been a very confusing recommendation for many, many years and it's hard to have a new recommendation every two or three years.” 他说：“多年来，肺炎球菌一直是一个非常令人困惑的建议，很难每两三年提出新的建议。”

The widespread use of pneumococcal conjugate vaccine (PCV) in children has dramatically lowered the incidence of pneumococcal disease through direct and indirect effects. Despite this progress, pneumococcal pneumonia still leads to more than 200,000 adult hospitalizations annually in the United States. Older adults, individuals with underlying health conditions, and certain racial groups continue to experience higher rates of pneumococcal disease. Dr. John Schoen, Senior Clinical Manager of Drug Information at the Vizient Center for Pharmacy Practice Excellence, joins Program Host Stacy Lauderdale to discuss the newest adult pneumococcal vaccine, PCV21, and recent updates to age-based pneumococcal vaccine recommendations.   Guest speakers:  John Schoen, Pharm.D, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence   Host:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence VerifiedRx Host   Show Notes:  [01:25-02:53] Background on PCV21 [02:54-07:56] Difference between PCV20 and PCV21 [07:57-16:15] Discussing the new ACIP recommendation to move the universal age for pneumococcal vaccination from 65 years of age down to 50 years of age and older [08:31-16:15] Why a healthy 50-year-old who has no risk factors for invasive pneumococcal disease should get a pneumococcal vaccination [16:16-17:57] Summary of other changes in the most recent MMWR [17:58-19:34] What organizations consider when selecting specific pneumococcal vaccines [19:35-21:18] What's in the pipeline for  pneumococcal vaccines   Links | Resources:  Publicly available resources Previous VerifiedRx podcasts on pneumococcal vaccines: What's pneu with pneumococcal vaccines? – March 29, 2022 What's pneu part 2: pneumococcal vaccines update – February 13, 2024 January 2024 MMWR - ACIP recommendations for the use of PCV in adults ≥ 50 years of age Vizient client exclusive resources 2025 pneumococcal vaccines side-by-side comparison   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Listen to the SBS Sinhala discussion on deadly Pneumococcal disease on the rise in Australia - ඕස්ට්‍රේලියාවේ වසර 20 ක ඉහළම අගයක් ගන්නා අසාදන අනුපාතයක් ඇති Pneumococcal disease යන බැක්ටීරියා ආසාදන තත්වය සහ එමගින් ආරක්ෂා වීමට කල යුතු දේ පිළිබඳව SBS සිංහල සේවය සිදු කල සාකච්චාවට සවන් දෙන්න

New research indicates that over ¾ people know little or nothing about pneumococcal disease, and that a majority don't know that its treatable by vaccine. This comes after a clear link between it and pneumonia has been identified. To discuss this further Pat was joined on the show by Dr Sumi Dunne Clinical Lecturer, General Practitioner, and a former ‘expert' on Operation Transformation.

To have your question featured in a future video, please email: questions@drmdc.health

Is a new COVID vaccine coming out? Which RSV vaccine is better? Are there new PCV vaccines? Which vaccines can be given together? When is the new flu shot available? Our guest is Sandra Fryhofer, MD, AMA's liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP's COVID-19 Vaccine Workgroup. American Medical Association CXO Todd Unger hosts.

There have been quite a few updates to certain vaccinations over the past several years, so Anna and I are here this week to review these important updates with you. Regardless of the population you care for, these vaccines are ones you'll see in your clinical rotations or in practice, and you'll probably be asked about them by your patients.   Tune in this week to learn the updates in indication, administration schedule, and important patient education guidance concerning RSV, COVID, pneumococcal, and meningococcal vaccinations.   Get full show notes and more information here: https://blog.npreviews.com/vaccination-updates-covid/

Visit nascentmc.com for the full writup of this episode and medical writing assistance.  Visit learnamastyle.com for free downloads directed towards medical writing and editing. • The FDA has approved the 21-valent pneumococcal conjugate vaccine, CAPVAXIVE™ (Merck), for the prevention of invasive disease and pneumonia in adults aged 18 years and older caused by 21 Streptococcus pneumoniae serotypes. Capvaxive includes eight serotypes not covered by other pneumococcal vaccines, addressing approximately 27% of IPD cases in adults aged 50 and older, and 30% in adults aged 65 and older, based on CDC data from 2018-2021. The approval follows an FDA Priority Review and is based on immune responses measured in the Phase 3 STRIDE-3 trial, with continued approval contingent upon verification of clinical benefit in a confirmatory trial.  • The FDA has approved delandistrogene moxeparvovec-rokl (Elevidys) for Duchenne muscular dystrophy (DMD) in ambulatory individuals aged 4 and older with a confirmed mutation in the DMD gene, as well as granting accelerated approval for non-ambulatory individuals. Elevidys, a one-time intravenous gene therapy, delivers a working copy of the DMD gene to address the muscle degeneration caused by mutations in this gene. The approvals are based on findings from a confirmatory trial that, while not meeting its primary endpoint, showed success in several secondary measures, with the Phase 3 ENVISION study underway to serve as a postmarketing requirement. • The FDA has approved adagrasib (Krazati) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Adagrasib targets the KRAS G12C mutation, a common driver mutation in several cancers including colorectal cancer, while cetuximab enhances its antitumor activity. The approval was based on findings from the KRYSTAL-1 trial, which demonstrated a confirmed overall response rate (ORR) of 34% and a median duration of response (DOR) of 5.8 months. • The FDA has approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel, followed by pembrolizumab monotherapy, to treat primary advanced or recurrent endometrial carcinoma in adults, marking the third endometrial carcinoma indication for Keytruda in the US. Keytruda enhances the body's immune response against tumor cells by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The approval is based on results from the phase 3 KEYNOTE-868 clinical trial, which demonstrated significant improvements in progression-free survival for patients treated with Keytruda plus chemotherapy compared to those receiving a placebo with chemotherapy.  • The FDA has approved risankizumab-rzaa (Skyrizi) for the treatment of moderately to severely active ulcerative colitis in adults, making it the first specific anti–interleukin 23 monoclonal antibody indicated for both ulcerative colitis and moderate to severe Crohn's disease. Risankizumab-rzaa inhibits interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses, thereby reducing inflammation. The approval is based on data from two phase 3 clinical trials, INSPIRE and COMMAND, which demonstrated the achievement of clinical remission and endoscopic improvement. • A supplemental Biologics License Application (sBLA) has been submitted for guselkumab (Tremfya) for the treatment of adults with moderately to severely active Crohn's disease. Guselkumab, a fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, was previously approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. Support for the BLA is based on findings from the Phase 3 GALAXI and GRAVITI clinical trials.

Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded.

Broadcast from KSQD Santa Cruz on 6-13-2024 Alzheimer's Disease and APOE4 Gene Listener asks about the APOE4 gene and its association with Alzheimer's disease in the light of a recent sensationalistic Nature publication. The impact of amyloid beta and TAU proteins on Alzheimer's pathology. Differences in Alzheimer's risk among different ethnic groups with APOE4 with emphasis on the importance of cholesterol levels as a risk multiplier. Advice for a listener's husband dealing with chronic back pain and sciatica Dr. Dawn presents a basic checklist for evaluating back pain symptoms and determining the need for urgent medical intervention. Potential causes are discussed such as spinal nerve compression from various sources. In this case, Dr. Dawn made a specific suggestion of McKenzie exercises and emphasized the importance of seeing a sports medicine doctor or physiatrist for a comprehensive evaluation. Dr. Dawn responds to a caller about managing knee osteoarthritis The role of glucosamine, chondroitin, and topical diclofenac in treatment. Discussion on non-pharmaceutical approaches like heat application and massage. Potential interventions like steroid injections, hyaluronic acid, platelet rich plasma and their benefits and risks. Dr. Dawn answers a question about dietary oxalates and their impact on kidney stones She emphasizes the importance of the oxalate content in foods and its limited role in kidney stone formation. She emphasizes the importance of hydration and maintaining a healthy microbiome. For specific dietary guidelines on oxalate in foods she suggests using oxalate.org. A concerned parent asks about aluminum and other vaccine adjuvants like formaldehyde for their infant's 2 month well child visit She expresses conflicting fears of being mischaracterized as a vaccine denier by merely expressing concern about vaccination for her infant. Dr. Dawn provides a breakdown of the necessity, immediate urgency and risks of each recommended vaccine (Hepatitis B, DTaP, Polio, Hib, Pneumococcal, Rotavirus) and suggests a social contextualization strategy to perhaps delay Polio, rotavirus and Hep B in this family's social context while emphasizing the importance of certain vaccinations to prevent serious illnesses. Dr. Dawn cites intriguing ambiguities in the literature that support the counterintuitive idea that smaller doses of aluminum may have a greater accumulation in tissues of brain and reproductive tissues than larger doses, and promises to research this further in a future program.

Broadcast from KSQD Santa Cruz on 6-13-2024 Alzheimer's Disease and APOE4 Gene Listener asks about the APOE4 gene and its association with Alzheimer's disease in the light of a recent sensationalistic Nature publication. The impact of amyloid beta and TAU proteins on Alzheimer's pathology. Differences in Alzheimer's risk among different ethnic groups with APOE4 with emphasis on the importance of cholesterol levels as a risk multiplier. Advice for a listener's husband dealing with chronic back pain and sciatica Dr. Dawn presents a basic checklist for evaluating back pain symptoms and determining the need for urgent medical intervention. Potential causes are discussed such as spinal nerve compression from various sources. In this case, Dr. Dawn made a specific suggestion of McKenzie exercises and emphasized the importance of seeing a sports medicine doctor or physiatrist for a comprehensive evaluation. Dr. Dawn responds to a caller about managing knee osteoarthritis The role of glucosamine, chondroitin, and topical diclofenac in treatment. Discussion on non-pharmaceutical approaches like heat application and massage. Potential interventions like steroid injections, hyaluronic acid, platelet rich plasma and their benefits and risks. Dr. Dawn answers a question about dietary oxalates and their impact on kidney stones She emphasizes the importance of the oxalate content in foods and its limited role in kidney stone formation. She emphasizes the importance of hydration and maintaining a healthy microbiome. For specific dietary guidelines on oxalate in foods she suggests using oxalate.org. A concerned parent asks about aluminum and other vaccine adjuvants like formaldehyde for their infant's 2 month well child visit She expresses conflicting fears of being mischaracterized as a vaccine denier by merely expressing concern about vaccination for her infant. Dr. Dawn provides a breakdown of the necessity, immediate urgency and risks of each recommended vaccine (Hepatitis B, DTaP, Polio, Hib, Pneumococcal, Rotavirus) and suggests a social contextualization strategy to perhaps delay Polio, rotavirus and Hep B in this family's social context while emphasizing the importance of certain vaccinations to prevent serious illnesses. Dr. Dawn cites intriguing ambiguities in the literature that support the counterintuitive idea that smaller doses of aluminum may have a greater accumulation in tissues of brain and reproductive tissues than larger doses, and promises to research this further in a future program.

Recorded and first published prior to the advent of PCV20.

Pink Sheet editors discuss Medicare spending projections for the Alzheimer's treatment Leqembi (:28), Janet Woodcock's new post-FDA role (12:28), and ongoing preparations for new pneumococcal vaccines that will reach the market soon (17:28). #business #pharma More On These Topics From The Pink Sheet Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer's Drug Costs: https://pink.citeline.com/PS150095/Medicare-Spending-Forecast-For-Leqembi-Reflects-CMS-Angst-About-Alzheimers-Drug-Costs Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm's Length: https://pink.citeline.com/PS150111/Woodcock-Takes-On-Rare-Disease-Challenges-In-Retirement-Keeps-FDA-Industry-At-Arms-Length Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck's V116: https://pink.citeline.com/PS150029/Change-Is-Constant-For-Pneumococcal-Vaccines-US-CDC-Prepares-For-Mercks-V116

Dr. Lisa Law and Dr. Randy Taplitz share the latest evidence-based recommendations from ASCO on vaccines in adults with cancer. They discuss recommended routine preventative vaccinations, additional vaccinations and revaccinations for adults undergoing HSCT, CD19 CAR-T treatment, or B cell-depleting therapy, guidance for adults with cancer traveling outside the U.S., and recommendations for vaccination of household and close contacts of adults with cancer. Dr. Law and Dr. Taplitz also share their insights on the guideline, including the importance of this guideline for adults with cancer and their clinicians, future advances in research, and current unmet needs. Read the full guideline, “Vaccination of Adults with Cancer: ASCO Guideline” at www.asco.org/supportive-care-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.00032       The ASCO Specialty Societies Advancing Adult Immunization (SSAAI) Project is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award to the Council of Medical Specialty Societies (CMSS) (with 100 percent funded by CDC/HHS). The contents are those of the authors and do not necessarily represent the official views of nor endorsement, by CDC/HHS or the U.S. Government. Brittany Harvey: Hello, and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today, I am interviewing Dr. Lisa Law from Kaiser Permanente and Dr. Randy Taplitz from City of Hope Comprehensive Cancer Center, authors on “Vaccination of Adults with Cancer: ASCO Guideline.” Thank you for being here, Dr. Law and Dr. Taplitz. Dr. Lisa Law: Thank you. Dr. Taplitz: Thank you, Brittany. Brittany Harvey: Before we discuss this guideline, I'd like to take note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplitz and Dr. Law, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.  So then, to dive into the content, here first, Dr. Taplitz, can you provide a general overview of both the scope and purpose of this guideline on vaccination of adults with cancer? Dr. Randy Taplitz: Yes, so people with cancer often experience a compromised immune system due to a variety of factors. This includes chronic inflammation, impaired or decreased function of the hematopoietic system, and treatments that compromise their immune function. Because of this, people with cancer are at a higher risk for infection, including with vaccine-preventable diseases. Also, response to vaccines in patients with cancer may well be affected by this underlying immune status, and their anticancer therapy, as well as the severity of the underlying malignancy. The purpose of vaccination in this group of patients is to prevent infection or to attenuate the severity of the disease when infection cannot be fully prevented.   This ASCO review builds on a 2013 guideline by the Infectious Diseases Society of America, or IDSA, and uses what's called a systematic literature review of 102 publications between 2013 and 2023. This includes 24 systematic reviews, 14 randomized clinical trials, and 64 non-randomized studies. The largest body of evidence in these studies, not surprisingly, addresses COVID vaccines on the efficacy and safety of vaccines used by adults with cancer or their household contacts. ASCO convened an expert panel to review this evidence and formulate recommendations for vaccinations in this population. Brittany Harvey: Understood. I appreciate that context, Dr. Taplitz. So then, next, Dr. Law, I'd like to review the key recommendations of this guideline. The guideline addresses four overarching clinical questions. So starting with the first question, what are the recommended routine preventative vaccinations for adults with cancer? Dr. Lisa Law: Thank you, Brittany. Before I start, I just want to wholeheartedly thank the first author of this paper, Dr. Mini Kamboj, Dr. Elise Kohn from the NCI, as well as the ASCO staff in putting this publication and guideline together. It is a very, very important guideline, and I echo everything Dr. Taplitz just said.  So going back to your question, what are the recommended routine preventative vaccines for adults with cancer? As per this guideline, there are about 7 to 8 based on patient age and risk. Namely, they are: seasonal flu, RSV for those aged 60 or above, COVID-19, Tdap, Hepatitis B, Shingrix, Pneumococcal vaccine, and the HPV vaccine. These vaccines should ideally be given two to four weeks before therapy. However, non-live vaccines can be given anytime during or after chemo, immunotherapy, hormonal treatment, radiation, or surgery. Brittany Harvey: Excellent. Thank you for reviewing those vaccinations and the timing of them as well. So then, following those recommendations, Dr. Taplitz, what additional vaccinations and revaccinations are recommended for adults undergoing hematopoietic stem cell transplantation, CD19 CAR-T treatment, or B-cell depleting therapy?  Dr. Randy Taplitz: Many studies have shown that stem cell transplant recipients essentially lose immunity from childhood immunizations, and we know that these individuals are very vulnerable to infection, particularly in the first year after transplant. Revaccination is critical to help restore their immunity. The optimal timing of vaccination is based on our understanding of adequate immune reconstitution with B and T-cell recovery so that the individual can mount a response to the vaccine. We know that a lot of factors influence this immune reconstitution, including the age of the stem cell transplant recipient, the source of the donor, the time from transplant, graft-versus-host disease prophylaxis, the treatment and severity of graft-versus-host disease, and the vaccine type and antigens used.   There are a number of bodies throughout the world, IDSA as I mentioned, CDC, American Society for Transplant and Cellular Therapy, European Society for Blood and Marrow Transplant, and European Conference for Infections and Leukemia. All of these bodies have guidelines that approach vaccination in stem cell transplants. However, variation does exist in the use of a variety of things including whether to use immune predictors to help guide vaccination, and there is really not consensus on whether this immune predictor guided vaccination is more likely to produce a protective immune response versus a standardized schedule. In addition, the duration of protection is incompletely understood.  The bottom line in these guidelines is that they recommend complete revaccination starting for most vaccines at 6 to 12 months after stem cell transplant, in order to restore vaccine-induced immunity. And I just want to go through a few of the particulars. For COVID-19, which is a three-dose series in the primary series, influenza - generally high-dose influenza - and pneumococcal vaccine, PCV20 in general, ultimately four doses, can be administered, starting as early as three months after transplant. Although there is really not much data to guide the use of the recombinant zoster vaccine in allogeneic stem cell transplant, the vaccine can be administered after the end of antiviral prophylaxis, which in general is 12 to 18 months after allogeneic and 3 to 12 months after autologous stem cell transplant. Some of the other vaccines, such as hepatitis B, Tdap, meningococcal vaccines, and HPV revaccination in those less than 45 are also recommended.   I want to also spend the moment talking about the two recently licensed RSV vaccines, which were essentially studied in less compromised hosts and really without any immunogenicity data in stem cell transplant, and thus, there is no recommendation in this guideline for the use of these vaccines after transplant. Live vaccines, such as MMR and varicella – varicella would be in varicella-seronegative patients without a prior history of varicella – should be delayed for at least two years and only given in the absence of active graft-versus-host disease or immunosuppression.  Moving briefly to CAR T, which is an immunotherapy that involves adoptive cell therapy, given the available data and after a review by the group, it was recommended that adults with hematopoietic malignancies receiving CAR T therapy directed against B-cell antigens should receive influenza and COVID-19 vaccines either two weeks before lymphodepletion or no sooner than three months after the completion of therapy. Administration of non-live vaccines preferably should occur before CAR T treatment or at least 6 to 12 months after, following the same timing as what we recommend for stem cell transplant. There is really little data to guide the safety and timing of administration of live vaccines after CAR T therapy.   In terms of adults receiving B-cell depleting therapy, they are generally unable for time to mount an effective humoral response but may have at least partially intact cellular immune responses. They are encouraged to be revaccinated for COVID-19 no sooner than six months after completion of B-cell depleting therapy, and they should receive influenza vaccine approximately four weeks from the most recent treatment dose for patients on chronic therapy. For other non-seasonal immunizations, vaccines ideally should be given two to four weeks before commencing anti-CD20 therapy or delayed until 6 to 12 months after completion, except for the recombinant zoster vaccine, which can be given one month after the most recent dose of B-cell depleting therapy. Brittany Harvey: I appreciate you reviewing each of those vaccinations and when they should be given, and reviewing the available data – albeit, limited data – in these situations.  So beyond these routine preventative vaccinations and revaccinations that you've both just described, Dr. Law, what additional vaccinations does the expert panel recommend for adults with cancer traveling outside the United States? Dr. Lisa Law: Good question. As per these ASCO guidelines, adults with solid or blood cancer traveling outside of the United States should follow the CDC standard recommendations for their destination. For the 2024 CDC Yellow Book, travel vaccines, in general, should be delayed until three months from the last chemotherapy or, and for those with solid tumors, ideally when the disease is in remission. Of note, hepatitis A, typhoid, inactivated polio, Hep B, rabies, meningococcal vaccine, and Japanese encephalitis vaccines are considered to be safe. In all cases of travel, patients should be counseled by their healthcare provider about the travel timing, with the additional attention to the regional seasonality of infections, for instance, influenza is more common in late summer in Australia, and also with attention to any outbreaks that may be occurring globally at the time of travel. Brittany Harvey: Absolutely. Those are key points for clinicians to discuss with their patients as they consider upcoming travel.  So then, the final clinical question that the panel addressed, Dr. Taplitz, what vaccinations does the panel recommend for household and close contacts of adults with cancer?  Dr. Randy Taplitz: Thank you. Yes, it is recommended that all household members and close contacts, when possible, be up to date on their vaccinations. And the only further thing I would say is that there are some special considerations for the use of live vaccines in household contacts, particularly in stem cell transplant recipients. Contacts of people who receive stem cell transplants should preferably receive inactivated influenza vaccines. As was mentioned, MMR and varicella vaccines are both safe to administer to close contacts. Vaccine strain transmission to immunocompromised hosts has not been associated with MMR use in family members.   Eleven cases of the varicella vaccine strain transmission are described in the published literature, but none occurred in compromised hosts. Because the vaccine strain can cause severe and fatal varicella in profoundly immunocompromised people, precautions are advised to avoid close contact with a person with a vaccine-induced rash. For household contact travelers, MMR and yellow fever vaccines are considered safe. Oral cholera should be avoided. For smallpox vaccines, the second-generation ACAM2000 has rarely been associated with vaccinia transmission and should be avoided because of this. But the live replication-deficient MVA-based JYNNEOS vaccine is felt to be safe for household contacts of immunocompromised individuals. Brittany Harvey: I appreciate you reviewing the importance of vaccination for household and close contacts, and some of those precautions that individuals should take. I appreciate you both for reviewing all of these recommendations.  So then in your view, Dr. Law, what is the importance of this guideline, and how will it impact both clinicians and adults with cancer? Dr. Lisa Law: In my opinion, this is a very important guideline that is long overdue in the oncology community and will have a huge impact on both clinicians and adults with cancer. Over the years, I have often been asked by my colleagues and patients, “Can I have the flu vaccine, and if so, when?” So this guideline really is going to be helpful. More importantly, our cancer patients are living much longer. They may have years of quality of life even with third or fourth line of treatment, especially, for instance, like CAR T for myeloma and lymphoma. However, we know that with additional treatment, that carries a substantial risk of infection complication among these immunocompromised patients. So it is of paramount importance to inform our patients and colleagues to be proactive in advocating preventive therapy ahead of time, meaning trying to get the patients appropriately vaccinated as early as possible to generate immunity.  Another case in point is the Shingrix vaccine. I used to see lots of shingles, but ever since we have the recombinant Shingrix, I have fewer encounters. And this is huge because post-herpetic neuralgia robs a patient's quality of life. So, again, it is very important to recommend appropriate vaccines for our cancer patients.  Brittany Harvey: Absolutely. It is key to ensure patients receive these preventative vaccines, and we hope that this guideline puts an emphasis on that for clinicians and patients.  So finally, to wrap us up, Dr. Taplitz, what are the current gaps in knowledge regarding the vaccination of people with cancer? Dr. Randy Taplitz: There are a number of really important gaps in knowledge and really critical unmet needs that require research and other dedicated efforts. Among these are, and I think paramount, are really the participation of people with cancer with varied types of immunocompromise in vaccine trials. Where vaccine trials are only for cancer patients, obviously is ideal, testing vaccines in the appropriate population. But when that's not feasible, pre-existing cancer should not preclude eligibility, and inclusion of cohorts of people receiving anticancer treatment should be incorporated prospectively. So that's really critical because the quality of our guidelines is based upon the data. We use the data for developing guidelines and gathering more data in the particular patient population is really, really critical.  Secondly, work for creating more immunogenic vaccines and research to understand the immune response to vaccines after immuno-depleting therapies, particularly with newer therapies such as CAR T and newer B cell therapies, bispecific antibodies, etc. is really critical. We need to really understand the immune response and have the most potent vaccines available to these people who may have impaired immune responses.  Switching gears a little bit, we really need mechanisms to promote institutional commitment to integrate and sustain immunization best practices for people with cancer. This will largely be through multidisciplinary, team-based approaches, protocol-based vaccination standing orders, and leveraging data sharing so that we can all be on the same page with giving vaccines to these individuals. We also need education and evidence-based decision-making tools, emphasizing preventive care through immunization, the availability of educational resources to clinicians and patients to address commonly asked questions and also misconceptions about vaccination, that's absolutely critical.  And finally, I think we need to develop strategies for addressing unique challenges and factors contributing to vaccine hesitancy during cancer therapy. We need to focus on patient and clinician communication, and very importantly, we need to consider health equity considerations in the development and approach to vaccines in these compromised patients. Brittany Harvey: Definitely, we'll look forward to research and advances in these areas that you've just described to support these guidelines and increase vaccine uptake.  So I want to thank you both so much for your work on this important guideline, and thank you for your time today, Dr. Law and Dr. Taplitz. Dr. Lisa Law: Thank you.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Pneumococcal vaccines have been instrumental in decreasing invasive disease since their introduction in the 1980s. 2021 brought regulatory changes and recent ACIP recommendations were published in the Morbidity and Mortality Weekly Report, also known as MMWR. Dr. John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information shares his insights on these changes with host Gretchen Brummel.      Guest speakers:   John Schoen, PharmD, BCPS Senior Clinical Manager of Evidence-Based Medicine and Drug Information Vizient Center for Pharmacy Practice Excellence      Host:   Gretchen Brummel, PharmD, BCPS   Pharmacy Executive Director   Vizient Center for Pharmacy Practice Excellence     Show Notes:   Recorded in the Fall of 2023 [01:00-03:34] What's new since March 2022 with pneumococcal vaccines  [03:35-06:51] Changes with the adult recommendations [06:52-13:10] New recommendations from CDC as well as published recommendations for adults [13:11-19:05] Recommendations for Pneumococcal vaccines in pediatrics [19:06-21:46] The area of biggest risk moving forward [21:47-24:07] What we are looking at for the future        Links | Resources:   Vizient pneumococcal vaccine side-by-side comparison Click Here ACIP pneumococcal vaccine recommendations Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

For the AMA Style cheat sheet learnamastyle.com See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights:  Test for Risk of Opioid Addiction:The FDA has approved AvertD by SOLVD Health, a test for assessing opioid addiction risk in individuals over 18, using genetic variants to evaluate addiction risk before prescribing oral opioids for acute pain; however, it's met with skepticism and not intended for chronic pain patients. https://www.cnn.com/2023/12/20/health/opioid-use-disorder-test-avertd/index.html https://avertdtest.com/  Filsuvez for Junctional Epidermolysis Bullosa:Filsuvez, a birch triterpenes topical gel, received FDA approval for treating Junctional and Dystrophic Epidermolysis Bullosa (JEB/DEB) in individuals aged 6 months and older, marking the first FDA-approved therapy for JEB's partial thickness wounds and a significant advancement in managing this debilitating skin disorder.https://resources.chiesiusa.com/Filsuvez/FILSUVEZ_PI.pdf Budesonide for IgA Nephropathy:Budesonide (Tarpeyo) received full FDA approval for reducing kidney function loss in adults with IgA nephropathy (IgAN), targeting specific antibodies implicated in IgAN based on phase 3 NefIgArd clinical trial data, marking the first FDA approval for IgAN treatment based on kidney function measures. https://www.tarpeyo.com/prescribinginformation.pdf Eplontersen for hATTR Polyneuropathy:Eplontersen (Wainua) was approved by the FDA for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR-PN), based on the NEURO-TTRansform Phase III trial, and is the only hATTR-PN treatment that can be self-administered via an auto-injector. https://pubmed.ncbi.nlm.nih.gov/37768671/ https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf NRX-101 for Complicated UTI:The FDA cleared an Investigational New Drug application for NRX-101, a D-cycloserine and lurasidone blend developed by NRx Pharmaceuticals for treating complicated urinary tract infections, with a pending request for Qualified Infectious Disease Product designation. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-fda-clearance-of-its-investigational-new-drug-ind-application-for-nrx-101-in-the-treatment-of-complicated-urinary-tract-infections-302017523.html?utm_source=pocket_saves Gefapixant for Chronic Cough:Merck's gefapixant, a selective antagonist of P2X3 receptors for treating chronic cough, was rejected by the FDA for the second time due to insufficient evidence of effectiveness in treating refractory or unexplained chronic cough in adults. https://www.businesswire.com/news/home/20231220302305/en/Merck-Provides-U.S.-Regulatory-Update-on-Gefapixant V116 for Invasive Pneumococcal Disease:Merck's V116, a 21-valent pneumococcal conjugate vaccine, was accepted by the FDA for priority review to prevent invasive pneumococcal disease in adults, based on STRIDE-3 Phase 3 trial data, with a target action date set for June 17, 2024. https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults Sotorasib in NSCLC:Lumakras (sotorasib), already under accelerated approval for KRASG12C-mutated non-small cell lung cancer (NSCLC), faces uncertainty for full FDA approval after an advisory committee voted against it, though it will remain available for clinical use.https://www.onclive.com/view/codebreak-200-sotorasib-in-second-line-kras-g12c-mutated-nsclc nascentmc.comlearnAMAstyle.com

Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joined Bob Sirott to talk about the latest health news. Dr. Marty talks about a new recommendation from the CDC concerning a pneumococcal vaccine for people who are nineteen years old and older.

In this episode Sean O'Leary, MD, MPH, FAAP, chair of the AAP Committee on Infectious Diseases, joins hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, for an “immunizations omnibus.” He describes newly approved products to protect against RSV, COVID and pneumococcal disease, and he predicts a difficult flu season. For resources go to aap.org/podcast.

Pneumococcal vaccination recommendations are arguably some of the most difficult to maneuver. With the approval of two new pneumococcal vaccines, guidelines have significantly changed. This podcast aims to discuss these changes in vaccines and recommendations, and provide resources to ensure patients are receiving the right vaccine at the right time. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Drs Michael S. Saag and David H. Spach discuss HIV and the nuances of primary care treatment, with a special focus on vaccines, including COVID, hepatitis, varicella zoster virus, and mpox. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986508). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview HIV and Immunizations https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-immunizations HRSA Ryan White HIV/AIDS Program https://ryanwhite.hrsa.gov/about/parts-and-initiatives Pneumococcal Vaccination https://www.cdc.gov/pneumococcal/vaccination.html Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Positive Individuals in the Era of Highly Active Antiretroviral Therapy https://pubmed.ncbi.nlm.nih.gov/30999829/ Pneumococcal 7-Valent Conjugate Vaccine https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pneumococcal-7-valent-conjugate-vaccine Immunizations for Preventable Diseases in Adults and Adolescents Living With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/immunizations Drug Database: Hepatitis B Vaccine https://clinicalinfo.hiv.gov/en/drugs/hepatitis-b-vaccine/patient Interpretation of Hepatitis B Laboratory Results https://www.cdc.gov/hepatitis/statistics/surveillanceguidance/docs/viral-hepatitis-surveillance-table-3-1_508.pdf Screening and Testing for Hepatitis B Virus infection: CDC Recommendations — United States, 2023 https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Hepatitis B Virus Infection https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-b-0?view=full Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-combination-regimens Cabotegravir/Rilpivirine (Rx) Cabenuva (cabotegravir/rilpivirine) dosing, indications, interactions, adverse effects, and more https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156 Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/ Systematic Review and Meta-analysis of Immune Response of Double Dose of Hepatitis B Vaccination in HIV-Infected Patients https://pubmed.ncbi.nlm.nih.gov/32334887/ Heplisav-B® (HepB-CpG) Vaccine https://www.cdc.gov/vaccines/schedules/vacc-updates/heplisav-b.html PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults https://pubmed.ncbi.nlm.nih.gov/35906803/ Hepatitis A Vaccine Inactivated (Rx) https://reference.medscape.com/drug/vaqta-havrix-hepatitis-a-vaccine-inactivated-343150 Hepatitis A/B Vaccine (Rx) https://reference.medscape.com/drug/twinrix-hepatitis-a-b-vaccine-343152 Zoster Vaccine Recombinant (Rx) https://reference.medscape.com/drug/shingrix-zoster-vaccine-recombinant-1000163 Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm#:~:text=On%20October%2020%2C%202021%2C%20ACIP,for%20use%20in%20immunocompromised%20persons. Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) https://www.cdc.gov/flu/prevent/nasalspray.htm MMR Vaccine https://www.ncbi.nlm.nih.gov/books/NBK554450/

In this episode of Matter of Vax Podcast, host Steph O'Connell interviews Professor Robert Booy about pneumococcal and meningococcal diseases. Pneumococcal and meningococcal are caused by a bacterium that can quickly lead to serious disease including pneumonia, meningitis and septicemia. Vaccination is critical for prevention. Professor Booy emphasizes the importance of implementing routine vaccination for all at-risk individuals to effectively combat these dangerous diseases. Visit Immunisation Foundation of Australia for more information Host Steph O'Connell is a public health advocate with 25 years' experience in strategic communications. She became a public voice for vaccinations when her daughter, Lily (23), narrowly survived W strain of Meningococcal on Christmas Day, 2017. Nine months later her sister, Grace, donated a kidney that has since transformed Lily's life.  Steph's advocacy for immunisation awareness and vaccination became a collaboration in 2018 with Meningococcal Australia and resulted in Meningococcal vaccination campaigns by the Australian Government Department of Health and NSW Health. Lily's story quickly resonated with audiences and became a national and international appeal for awareness, education and vaccination.  Steph's work expanded during the pandemic and today she continues to advocate for improved access to vaccines, public education for lifelong vaccination behaviour and policy reform. MatterofVax, in collaboration with Immunisation Foundation of Australia takes a look at topical immunisation issues on video and podcast.  Matter of Vax is produced by Ampel, for Immunisation Foundation of Australia. See omnystudio.com/listener for privacy information.

Tune in to hear Charles Jones, Vaccine Industry Leader at Pfizer, discuss the future of vaccines in the marketplace. Topics include: Changes seen in the marketplace and the competitive landscape Challenges of the changing schedule for preventative products such as flu immunization, COVID-19, Pneumococcal, shingle vaccines, and moreThe role of policy makers, like The Advisory Committee on Immunization Practices (ACIP) in the US and all the various participants, and the impacts they have on the value chain and the future of the ecosystemSpeakers:Charles Jones, Vaccine Industry Leader, Pfizer Amy Hunckler, Pharma and Life Sciences Managing Director, PwC May Weiser, Pharma and Life Sciences Director, PwC Igor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

- How to Protect Yourself & Your Loved Ones from COVID, Omicron & Delta Variants - COVID Vaccines & Booster Vaccines - Other Vaccines - Flu, Pneumococcal & Shingles Vaccines - COVID & People Living with Cancer - Where to Find Reliable Information Regarding this Pandemic & Its Variants - How to Protect Yourself, Loved Ones & Children from COVID & Its Variants - The Increasing Role of Telemedicine/Telehealth Appointments - How to Prepare for Your Telemedicine/Telehealth Appointments, including Prepared List of Questions, Follow-Up Appointments, Quality-of-Life Concerns & Discussion of OpenNotes - Working Closely with Your Health Care Team about Your Wishes & Health Care Directives - Tips to Manage the Practical, Emotional & Financial Stresses Related to COVID, Omicron Variants & Cancer - Self-Care & Stress Management Tips - Questions for Our Panel of Experts

- How to Protect Yourself & Your Loved Ones from COVID, Omicron & Delta Variants - COVID Vaccines & Booster Vaccines - Other Vaccines - Flu, Pneumococcal & Shingles Vaccines - COVID & People Living with Cancer - Where to Find Reliable Information Regarding this Pandemic & Its Variants - How to Protect Yourself, Loved Ones & Children from COVID & Its Variants - The Increasing Role of Telemedicine/Telehealth Appointments - How to Prepare for Your Telemedicine/Telehealth Appointments, including Prepared List of Questions, Follow-Up Appointments, Quality-of-Life Concerns & Discussion of OpenNotes - Working Closely with Your Health Care Team about Your Wishes & Health Care Directives - Tips to Manage the Practical, Emotional & Financial Stresses Related to COVID, Omicron Variants & Cancer - Self-Care & Stress Management Tips - Questions for Our Panel of Experts

A recent study from Otago University, Christchurch supports the need for a stronger strain of immunisations against pneumococcal, know as PVC-13. Co-author of the study, Professor Tony Walls speaks to Jesse.

On episode #9 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the previous two weeks, 8/4/22 – 8/17/22.   Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of Puscast! Links for this episode Zoonotic henipavirus in febrile patients in China (NEJM) Role of prospective monitoring, pre-emptive and prophylactic therapy for human Herpesvirus-6 after stem cell transplantation (OFID) Tuberculosis outbreak in the USA linked to bone graft product (Lancet ID) Surgical and medical management of Diabetic Foot Osteomyelitis (OFID) Increase in Pediatric Intracranial Infections during COVID-19 Pandemic (CDC) Incidence of Acute Chest Syndrome in children with Sickle Cell Disease following Pneumococcal vaccine (JAMA) Antibiotic resistance genes in the gut microbiota of mothers (Nature Microbiology) Clinical characteristics, health care utilization, and outcomes among patients for Invasive Mold Disease (OFID) Low-Dose subcutaneous/intravenous Monoclonal Antibody to prevent Malaria (NEJM) Revisiting practice of the treatment of Toxoplasmic Encephalitis Phase two trial of oral fexinidazole in adults with chronic indeterminate Chagas disease (CID) Half of human pathogenic diseases can be aggravated by climate change (Nature) The Impact of standardized infectious diseases consultation on Postsplenectomy care and outcomes Potential value and patient confidentiality implications of infectious disease clinician peer consultations via social media (OFID) Music is by Ronald Jenkees

In this episode, we will discuss the rationale behind the FDA approval of two new pneumococcal conjugate vaccines (PCV20 and PCV15), the characteristics of these vaccines, their place in therapy as recommended by the ACIP, and subsequent CDC immunization schedule changes. Key Concepts Pneumococcal disease is mainly caused by various serotypes of Streptococcus pneumoniae and presentation can vary from mild forms (sinusitis, otitis media) to more severe (pneumonia, bacteremia, or meningitis). Previously we used PCV13 and PPSV23 vaccines for adults ages 18 years and older for prevention of pneumococcal disease, but the recommendations were rather complicated based on age, underlying condition/immune status, and vaccination status.  Two new conjugate-type pneumococcal vaccines, PCV20 (Prevnar 20) and PCV15 (Vaxneuvance) are now approved by the FDA and were recently added to the CDC's adult immunization schedules. These updated recommendations are more simplified where adults with high-risk conditions and those ages 65 years and older should receive either 1 dose of PCV20 vaccine or 1 dose of PCV15 and then 1 dose of PPSV23 a year later to complete their pneumococcal vaccine series.   PCV15 is now FDA approved for children and updated recommendations for children have been voted upon by the Advisory Committee on Immunization Practices (ACIP) and will be final once it is made official policy by the CDC. References and Resources Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. 2022;71(4);109–117. https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Hall E., Wodi A.P., Hamborsky J., et al., eds. Washington DC: Public Health Foundation; 2021. Goldblatt D, O'Brien KL. Pneumococcal Infections. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine 21e. McGraw Hill; 2022. Accessed August 04, 2022. Wagner AL, Boulton ML. Pneumococcal Infections. In: Boulton ML, Wallace RB. eds. Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e. McGraw Hill; 2022. Accessed August 04, 2022. CDC's PneumoRecs VaxAdvisor mobile app: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html CDC's Pneumococcal vaccine timing for adults: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf

In this week's episode, we discuss the "ACR's 2022 Guideline Summary for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases" with lead author Dr. Anne Bass, Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and a Professor of Clinical Medicine at Weill Cornell Medicine. During our conversation we consider the importance of guidelines for vaccines, the impact certain drugs like rituximab and methotrexate have on vaccinations, cover some vaccine highlights within the guidelines, how these guidelines can aid in navigation with insurance companies and much, much more. 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-277 Overview: Join us to discuss a summary of the newly published guidelines for pneumococcal vaccines and to review the most recently approved vaccines. We'll begin by describing the challenges from the previous guidelines and how these new guidelines address these challenges. Given the burden of pneumococcal disease and that vaccination is our best weapon to combat the disease, you won't want to miss this episode.  Episode resource links: Morga, A., Kimura, T., Feng, Q., Rozario, N., & Schwartz, J. (2022). Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination. Vaccine.   https://www.medscape.com/viewarticle/967675#vp_1   Schulz, P. S., Moore, S. E., Smith, D., Javed, J., & Wilde, A. M. (2022, April). Missed Pneumococcal Vaccination Opportunities in Adults With Invasive Pneumococcal Disease in a Community Health System. In Open Forum Infectious Diseases (Vol. 9, No. 4, p. ofac075). US: Oxford University Press.   Center for disease Control and Prevention Resources: App for iphone and android PneumoRecs Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Richard Onorato

Continuing on with our 2 month vaccines according to the CDC schedule, we are diving into the pneumococcal vaccine and all the the things regarding this disease, the vaccine, the ingredients, the side effects and more.One of the most common causes for irritability in babies comes from this vaccine, that MANY parents don't even realize are being given to their children.Informed consent is SO So important! Subscribe and hang out with me every Wednesday to stay up to date on this show.  If you enjoy, please share this on your social media and tag me (@brookebrewer20) and give me a rating/review. Thank you!For Text updates when each episode releases textPODCAST to (248) 301-9919 Sponsors:Get your Fat Burning Collagen today (linked the chocolate flavored goodness)https://modere.co/3jxbzyBUse code 4842132 to save $10 off your first orderShow notes and references: Current CDC Vaccine Schedulehttps://www.cdc.gov/vaccines/schedules/index.htmlFDA website for package inserts: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htmVaccine Ingredient Summary https://vaccine.guide/vaccine-ingredients/overview/cdc-vaccine-excipient-and-media-summary/Vaccine Glossery and Detailshttps://vaccine.guide/vaccine-ingredients/overview/vaccine-ingredient-glossary-and-details/Harvard Study on VAERS reporting https://vaccine.guide/ncvia-vicp-vaers/vaccine-adverse-events-reporting-system/hhs-funded-vaers-investigation/Pneumococcal Diseasehttps://www.cdc.gov/pneumococcal/index.htmlPrevnar13 Inserthttps://vaccine.guide/vaccine-inserts/pneumococcal/prevnar-13/The vaccine conversationhttp://www.thevaccineconversation.com 

Researchers look to licorice for promising cancer treatments   University of Illinois Chicago, April 6, 2022   Licorice is more than a candy people either love or hate—it may play a role in preventing or treating certain types of cancer, according to researchers at the University of Illinois Chicago. Gnanasekar Munirathinam and his research team are studying substances derived from the licorice plant Glycyrrhiza glabra to determine if they could be used to prevent or stop the growth of prostate cancer. "When we look at the research out there and our own data, it appears that glycyrrhizin and its derivative glycyrrhetinic acid have great potential as anti-inflammatory and anti-cancer agents," Munirathinam said. "We hope our research on prostate cancer cells advances the science to the point where therapies can be translated to help prevent or even cure prostate and other types of cancer."   (NEXT)   Not all dietary fiber is equal: Cereal fiber linked with lower inflammation, but not fruit or vegetable fiber   Columbia University, April 6, 2022   Researchers at Columbia University Mailman School of Public Health and colleagues evaluated whether dietary fiber intake was associated with a decrease in inflammation in older adults and if fiber was inversely related to cardiovascular disease. The results showed that total fiber, and more specifically cereal fiber but not fruit or vegetable fiber, was consistently associated with lower inflammation and lower CVD incidence. The research confirmed previously observed associations between dietary fiber and CVD and extended those investigations to include the source of the fiber, the relationship of fiber with multiple inflammatory markers, and to test whether inflammation mediated the relationship between dietary fiber and CVD.   (NEXT)   How to reduce loneliness: Meaningful activities can improve health, well-being   Pennsylvania State University   Free time is sometimes idealized, but research shows free time can sometimes be unhealthy by increasing loneliness. A new Penn State study demonstrated that engaging in meaningful, challenging activities during free time can reduce people's loneliness and increase their positive feelings. Across two different studies, the researchers found that people who had meaningful, challenging experiences were less lonely—even when higher levels of social contact and support were not available. Our research shows that both of these ideas are true. By engaging in meaningful activities during free time that demand focus, people can reduce loneliness and increase momentary happiness."  "Loneliness is very connected to our health," Dattilo explained. "Psychological, emotional, and cognitive health are all challenged when people are lonely. Loneliness is associated with depression and other mental health challenges."   (NEXT)   Curcumin Found To Outperform Pneumococcal Vaccines In Protecting Infants   UCLA, April 1, 2022   Now new research finds a substance in turmeric, curcumin, may outperform the vaccine in providing long lasting protection against potentially deadly lung damage in infants. Pneumococcal bacteria are the most common cause of bacterial infections in children and a frequent cause of infections in adults. Infection starts in the nose or throat where it may persist for weeks or months. Pneumococcal infections are also the most common complication of seasonal influenza. Researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), using disease models, found curcumin provided long-term protection against the damage caused by inadequate lung function. Their study, published online by the American Journal of Physiology, Lung Cellular and Molecular Physiology, found curcumin provided protection against bronchopulmonary dysplasia (BDP), a condition characterized by scarring and inflammation, and against hyperoxia, in which too much oxygen enters the body through the lungs.   Scott Ritter   via ZOOM   Scott Ritter is a former US Marine Corp intelligence officer and military strategist during the Cold War with the Soviet Union and in the Middle East. He served as a lead analyst for Marine deployment during the Soviet invasion of Afghanistan and the Iran-Iraq war. During Operation Desert Storm, Scott was the ballistic missile advisor to General Schwarzkopf. Later he assumed the role of the lead United Nations weapons inspector for seven years overseeing the disarmament of Iraq's weapons of mass destruction and biological agents program. He was one of the most forceful critics of the Bush administration's claims that Sadaam Hussain possessed WMDs. Scott is now an author and lecturer who has been very public about the American media's misinformation campaign about Russia's incursion into Ukraine and the gross failure's of the Biden White House foreign affairs policies and actions.